Effects of Nilotinib on Platelet Function in Patients with Chronic Myeloid Leukemia in Chronic Phase

Overview

Journal Leuk Res Rep

Date 2019 Jul 12

PMID 31293883

Authors

Alauldeen Mudhafar Zubair Alqasim

Ghasaq Mohsin Obaid

Yusra Ghaith Yaseen

Alaa Fadhil Alwan

Affiliations

Soon will be listed here.

Abstract

Background: Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions.

Objectives: Evaluate the effects of nilotinib on platelets aggregation in 42 patients with chronic phase of CML and correlate the results with clinical and hematological parameters: age, complete blood count and presentation.

Patients And Methods: This study was conducted on 42 patients diagnosed as Chronic Phase of Chronic Myeloid Leukemia based on clinical, morphological and cytogenetic study. All patients were on Nilotinib treatment and were attending the National Center of Hematology in Baghdad. About 9 mL of venous blood sample were collected from each patient and control subjects, samples divided into 3 parts for complete blood count, platelet aggregation test and PT and aPTT.

Results: The mean age was 41.3 ± 1.7 (mean ± SEM) years old. M:F ratio of 1.2:1. Mean duration of nilotinib therapy(1.4 years). All patients had normal PT and aPTT.Only 16 (38%) patients had abnormal aggregation response to epinephrine, but there was no statistically significant differences with control group.

Conclusion: Nilotinib had no adverse effect on platelet function nor patients clotting tests.

Citing Articles

Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks.

Diaz-Santiago E, Moya-Garcia A, Perez-Garcia J, Yahyaoui R, Orengo C, Pazos F Front Pharmacol. 2025; 15:1470931.

PMID: 39911831 PMC: 11794328. DOI: 10.3389/fphar.2024.1470931.

References

Ghanei M, Vosoghi A . An epidemiologic study to screen for chronic myelocytic leukemia in war victims exposed to mustard gas. Environ Health Perspect. 2002; 110(5):519-21. PMC: 1240841. DOI: 10.1289/ehp.02110519. View

Avram S, Lupu A, Angelescu S, Olteanu N . Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med. 2002; 5(1):79-87. PMC: 6737776. DOI: 10.1111/j.1582-4934.2001.tb00140.x. View

Usman M, Syed N, Kakepoto G, Adil S, Khurshid M . Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India. 2007; 55:103-7. View

Kantarjian H, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F . Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110(10):3540-6. DOI: 10.1182/blood-2007-03-080689. View

Quintas-Cardama A, Han X, Kantarjian H, Cortes J . Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114(2):261-3. PMC: 3952950. DOI: 10.1182/blood-2008-09-180604. View

Kantarjian H, Giles F, Bhalla K, Pinilla-Ibarz J, Larson R, Gattermann N . Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2010; 117(4):1141-5. PMC: 4916554. DOI: 10.1182/blood-2010-03-277152. View

Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M . Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report. J Med Case Rep. 2011; 5:215. PMC: 3117828. DOI: 10.1186/1752-1947-5-215. View

Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M . Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011; 155(1):30-44. DOI: 10.1111/j.1365-2141.2011.08793.x. View

Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D . Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica. 2012; 97(9):1444. PMC: 3436248. DOI: 10.3324/haematol.2012.064618. View

10.

Sahin F, Saydam G, Comert M, Uz B, Yavuz A, Turan E . Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turk J Haematol. 2014; 30(4):351-8. PMC: 3874976. DOI: 10.4274/tjh.2013.0151. View

11.

Matti B, Alwan A . Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study. Turk J Haematol. 2014; 30(4):387-93. PMC: 3874977. DOI: 10.4274/Tjh.2012.0135. View

12.

Romero M, Chavez D, De Los Rios M, Alvis-Guzman N . Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014; 34(1):48-59. DOI: 10.1590/S0120-41572014000100008. View

13.

Jain P, Das V, Ranjan A, Chaudhary R, Pandey K . Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. J Res Pharm Pract. 2014; 2(4):156-61. PMC: 4076923. DOI: 10.4103/2279-042X.128145. View

14.

Loren C, Aslan J, Rigg R, Nowak M, Healy L, Gruber A . The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2014; 135(1):155-60. PMC: 4272760. DOI: 10.1016/j.thromres.2014.11.009. View